Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.51 |
| ▸ | F7 | P08709 | 4/20 | 0.51 |
| ▸ | F3 | P13726 | 4/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.51 |
| ▸ | PPARG | P37231 | 3/20 | 0.51 |
| ▸ | PPARD | Q03181 | 3/20 | 0.51 |
| ▸ | PPARA | Q07869 | 3/20 | 0.51 |
| ▸ | FABP3 | P05413 | 3/20 | 0.51 |
| ▸ | FFAR1 | O14842 | 3/20 | 0.51 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.51 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.51 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.51 |
| ▸ | FABP4 | P15090 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | GNA15 | P30679 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28450589 | 0.96 | EPHX2 (0.50) | F7F3PPARGPPARDPPARA | |
| SCHEMBL14842989 | 0.80 | CNR1 (0.59) | ALDH1A1F7F3KDM4EPPARG | |
| SCHEMBL3775009 | 0.77 | ALDH1A1 (0.67) | ALDH1A1F7F3KDM4EPPARG | |
| SCHEMBL19692318 | 0.77 | EPHX2 (0.47) | F7F3PPARGPPARDPPARA | |
| SCHEMBL977421 | 0.77 | EPHX2 (0.47) | F7F3PPARGPPARDPPARA | |
| SCHEMBL17183003 | 0.77 | EPHX2 (0.47) | F7F3PPARGPPARDPPARA | |
| SCHEMBL6686505 | 0.77 | TERT (0.66) | F7F3PPARGPPARDPPARA | |
| SCHEMBL28984567 | 0.77 | TERT (0.66) | F7F3PPARGPPARDPPARA | |
| SCHEMBL28984566 | 0.77 | TERT (0.66) | F7F3PPARGPPARDPPARA | |
| SCHEMBL633815 | 0.77 | TERT (0.66) | F7F3PPARGPPARDPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 322 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4687990-A1 | METHOD OF SYNTHESIS OF TARGETED LIPID NANOPARTICLE AND USES THEREOF | OSE IMMUNOTHERAPEUTICS (FR) | 2026-02-11 | — | — | EP | claimed |
| WO-2024200820-A1 | METHOD OF SYNTHESIS OF TARGETED LIPID NANOPARTICLE AND USES THEREOF | OSE IMMUNOTHERAPEUTICS (FR) | 2024-10-03 | — | — | WO | claimed |
| EP-4387657-A1 | LIPID NANOPARTICLE FORMULATIONS | Monash University (AU) | 2024-06-26 | — | — | EP | claimed |
| EP-4376883-A2 | RNA VACCINES | Arcturus Therapeutics, Inc. (US) | 2024-06-05 | — | — | EP | claimed |
| WO-2023019310-A1 | LIPID NANOPARTICLE FORMULATIONS | MONASH UNIVERSITY (AU) | 2023-02-23 | — | — | WO | claimed |
| WO-2023010128-A2 | RNA VACCINES | ARCTURUS THERAPEUTICS, INC. (US) | 2023-02-02 | — | — | WO | claimed |
| EP-3852727-A1 | THERAPEUTIC NANOPARTICLES AND METHODS OF USE THEREOF | Universiteit Gent (BE) | 2021-07-28 | — | — | EP | claimed |
| WO-2020058239-A1 | THERAPEUTIC NANOPARTICLES AND METHODS OF USE THEREOF | UNIVERSITEIT GENT (BE) | 2020-03-26 | — | — | WO | claimed |
| JP-2011507534-A | — | — | 2011-03-10 | — | — | JP | claimed |
| EP-2238251-A1 | SILENCING OF POLO-LIKE KINASE EXPRESSION USING INTERFERING RNA | Protiva Biotherapeutics Inc. (CA) | 2010-10-13 | — | — | EP | claimed |
| WO-2009082817-A1 | SILENCING OF POLO-LIKE KINASE EXPRESSION USING INTERFERING RNA | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2009-07-09 | — | — | WO | claimed |
| EP-4746902-A2 | COMPOSITIONS FOR DELIVERY OF PLASMODIUM ANTIGENS AND RELATED METHODS | BioNTech SE (DE) | 2026-05-27 | — | — | EP | disclosed |
| EP-4704891-A1 | OPTIMIZED CSP VARIANTS AND RELATED METHODS | BioNTech SE (DE) | 2026-03-11 | — | — | EP | disclosed |
| EP-4704875-A2 | COMPOSITIONS AND METHODS FOR TREATMENT OF SEPTIC SHOCK | PEROXITECH INC. (US) | 2026-03-11 | — | — | EP | disclosed |
| WO-2026047716-A1 | SARS-COV-2 VACCINES AND THERAPEUTICS | POPVAX PRIVATE LIMITED (IN) | 2026-03-05 | — | — | WO | disclosed |
| EP-2279254-A1 | NOVEL LIPID FORMULATIONS FOR NUCLEIC ACID DELIVERY | Protiva Biotherapeutics Inc. (CA) | 2011-02-02 | — | — | EP | disclosed |
| EP-2238251-A1 | SILENCING OF POLO-LIKE KINASE EXPRESSION USING INTERFERING RNA | Protiva Biotherapeutics Inc. (CA) | 2010-10-13 | — | — | EP | disclosed |
| WO-2009127060-A1 | NOVEL LIPID FORMULATIONS FOR NUCLEIC ACID DELIVERY | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2009-10-22 | — | — | WO | disclosed |
| WO-2009129319-A2 | SILENCING OF CSN5 GENE EXPRESSION USING INTERFERING RNA | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2009-10-22 | — | — | WO | disclosed |
| WO-2009082817-A1 | SILENCING OF POLO-LIKE KINASE EXPRESSION USING INTERFERING RNA | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2009-07-09 | — | — | WO | disclosed |